Abcuro

Abcuro develops immunotherapies for autoimmune disease and cancer. Its lead antibody targets KLRG1 to treat inclusion body myositis.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2020
Abcuro Portco Hover Image sm